logo-loader
viewFaron Pharmaceuticals Ltd

'Immune activation from Clevegen has now been demonstrated' Faron Pharma CEO

Faron Pharmaceuticals Oy's (LON:FARN) Markku Jalkanen caught up with Proactive London's Andrew Scott to discuss the recently released Matins trial update which is assessing the firm's drug Clevegen.

He says feedback from the dose escalation study confirmed Clevegen has good tolerability across all dosing levels tested and that, surprisingly, lower doses could potentially induce a stronger immune response.

''I feel extremely confident at the moment absolutely'', Jalkanen says.

''The clinical benefits have already been seen which we didn't anticipate at this early stage because it was more about dose escalation.

''2020 will be a very interesting year for us''.

Quick facts: Faron Pharmaceuticals Ltd

Price: 232.5 GBX

AIM:FARN
Market: AIM
Market Cap: £100.65 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Faron Pharmaceuticals makes 'groundbreaking discovery' in its MATINS trial

Faron Pharmaceuticals Oy (LON:FARN) (FIRSTNORTH:FARON) CEO Dr Markku Jalkanen speaks to Proactive London's Andrew Scott after updating on its phase I/II MATINS trial of Clevegen. He says it's been encouraging to discover that Clevegen can ‘down’ regulate a range of checkpoints that affect the...

on 12/12/19

2 min read